Immunitybio Inc
immunitybio.comImmunityBio Inc (NASDAQ: IBRX) is a clinical-stage biopharmaceutical company that develops and commercializes immunotherapy treatments for cancer and infectious diseases. Revenue is generated through commercialization of its approved product ANKTIVA, with the company relying on third-party contract manufacturers (CMOs), contract research organizations (CROs), and sales and marketing service providers to support operations. ImmunityBio depends on third and related parties for manufacturing, distribution, government price reporting, customer service, accounts receivable management, cash collection, and adverse event reporting, as disclosed in its 10-K filed February 23, 2026. The company is seeking incremental regulatory approvals for ANKTIVA internationally while running large-scale clinical trials for additional product candidates. As a commercial-stage company still heavily dependent on external partners and ongoing clinical programs, it carries material execution risk tied to regulatory timelines, manufacturing compliance with cGMP standards, and clinical trial adherence to GCP guidelines.
Products & Services
ANKTIVA (approved immunotherapy product); additional oncology and infectious disease product candidates in clinical development.
Revenue Model
Product revenue from commercialization of ANKTIVA, its FDA-approved immunotherapy. Third-party service providers handle distribution, government price reporting, and cash collection on the company's behalf.
Customers & Markets
Oncology and infectious disease end markets. Specific customer names, counts, or concentration data are not disclosed in the provided filing excerpts.
Geographic Exposure
Pursuing international regulatory approvals for ANKTIVA, indicating a U.S. commercial base with international expansion underway. Specific geographic revenue breakdown is not disclosed in the provided filing excerpts.
Financial Snapshot
Loading...
